

Hypertension in the Very Elderly Trial

Submission date 18/11/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 18/11/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 14/11/2013	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Professor CJ Bulpitt

Contact details
Care of the Elderly
Division of Medicine
ICSM at Hammersmith Hospital
Du Cane Road
London
United Kingdom
W12 0NN
+44 (0)20 8383 3959
c.bulpitt@ic.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00122811

Secondary identifying numbers
RG/97010

Study information

Scientific Title

Acronym

HYVET

Study objectives

To assess the benefits of treating very elderly patients with hypertension.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the relevant central and local ethics committees

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Hypertension

Interventions

Two treatment groups:

1. Placebo
2. Indapamide Sustained Release (SR) 1.5 mg plus perindopril 2 - 4 mg if required.

Goal: diastolic blood pressure less than 80 mmHg with systolic pressure less than 150 mmHg.

The patients are followed-up both according to clinical need and every 3 months in the first year and every 6 months thereafter.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Indapamide Sustained Release (SR), perindopril

Primary outcome measure

Stroke events (fatal and non-fatal).

Secondary outcome measures

1. Total mortality
2. Cardiovascular mortality
3. Cardiac mortality
4. Stroke mortality
5. Skeletal fracture

Overall study start date

01/01/2001

Completion date

31/12/2009

Eligibility**Key inclusion criteria**

1. People 80 years old and above
2. Sustained systolic pressure 160 - 199 mmHg and diastolic (phase V) pressure 90 - 109 mmHg
3. No evidence of renal failure or co-morbidity requiring anti-hypertensive treatment

Participant type(s)

Patient

Age group

Senior

Sex

Both

Target number of participants

2100

Key exclusion criteria

Does not comply with above inclusion criteria.

Date of first enrolment

01/01/2001

Date of final enrolment

31/12/2009

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Care of the Elderly

London

United Kingdom

W12 0NN

Sponsor information

Organisation

British Heart Foundation (UK)

Sponsor details

14 Fitzhardinge Street

London

United Kingdom

W1H 6DH

+44 (0)20 7935 0185

research@bhf.org.uk

Sponsor type

Charity

Website

<http://www.bhf.org.uk/>

ROR

<https://ror.org/02wdwnk04>

Funder(s)

Funder type

Charity

Funder Name

British Heart Foundation (UK) (ref: RG/97010)

Alternative Name(s)

the_bhf, The British Heart Foundation, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

Institut de Recherches Internationales Servier (France)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	main trial protocol	01/07/2001		Yes	No
Protocol article	sub-study protocol	19/12/2006		Yes	No
Results article	results	01/05/2008		Yes	No
Results article	results	01/07/2010		Yes	No